885590-85-2

Usage

Molecular Structure

2-(2,3-difluorophenyl)-2-methyl[1,3]dioxolane is a chemical compound that consists of a dioxolane ring with a 2-methyl-2-(2,3-difluorophenyl) substituent.

Chemical Class

It belongs to the class of dioxolanes.

Usage

It is commonly used as a precursor or intermediate in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals.

Unique Properties

The difluorophenyl group provides 2-(2,3-difluorophenyl)-2-methyl[1,3]dioxolane with unique properties and functionalities, making it useful in various chemical synthesis applications.

Reactivity

The presence of the dioxolane ring contributes to the compound's reactivity and potential for diverse chemical transformations.

Upstream product

• 18355-80-1 2,3-difluoroacetophenone 
• 107-21-1 ethylene glycol 

Downstream Products

• 885590-87-4 C₁₀H₉F₂IO₂ 
• 1007346-27-1 2-(4-bromo-2,3-difluorophenyl)-2-methyl[1,3]dioxolane 

Relevant academic research and scientific papers

7-Fluoroindazoles as potent and selective inhibitors of factor Xa

We have developed a novel series of potent and selective factor Xa inhibitors that employ a key 7-fluoroindazolyl moiety. The 7-fluoro group on the indazole scaffold replaces the carbonyl group of an amide that is found in previously reported factor Xa inhibitors. The structure of a factor Xa cocrystal containing 7-fluoroindazole 51a showed the 7-fluoro atom hydrogen-bonding with the N-H of Gly216 (2.9 ?) in the peptide backbone. Thus, the 7-fluoroindazolyl moiety not only occupied the same space as the carbonyl group of an amide found in prior factor Xa inhibitors but also maintained a hydrogen bond interaction with the protein's β-sheet domain. The structure-activity relationship for this series was consistent with this finding, as the factor Xa inhibitory potencies were about 60-fold greater (ΔΔG ≈ 2.4 kcal/mol) for the 7-fluoroindazoles 25a and 25c versus the corresponding indazoles 25b and 25d. Highly convergent synthesis of these factor Xa inhibitors is also described.

FACTOR XA COMPOUNDS

The present invention is directed to novel compounds of Formula (I) and forms and pharmaceutical compositions thereof, and the use thereof as inhibitors of Factor Xa.